MoneyWorks4Me

Unjha Formulations - Quaterly Results

19 May 2026 Evaluate
The Sales for the quarter ended March 2026 of Rs. 33.28 millions rose by 36.45% from Rs. 24.39 millions.The Net Loss for the quarter ended March 2026 is Rs. -7.44 millions as compared to Net Loss of Rs. -4.07 millions of corresponding quarter ended March 2025 Operating profit Margin for the quarter ended March 2026 further decreased to -4.48% as compared to -2.59% of corresponding quarter ended March 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 33.28 24.39 36.45 157.49 139.77 12.68 157.49 139.77 12.68
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT -4.48 -2.59 72.97 11.04 6.30 75.24 11.04 6.30 75.24
Interest 0.03 -0.01 -400.00 0.08 0.08 0.00 0.08 0.08 0.00
PBDT -4.51 -2.58 74.81 10.96 6.22 76.21 10.96 6.22 76.21
Depreciation 0.44 0.33 33.33 1.42 0.98 44.90 1.42 0.98 44.90
PBT -4.95 -2.91 70.10 9.54 5.24 82.06 9.54 5.24 82.06
TAX 2.49 1.16 114.66 2.49 1.16 114.66 2.49 1.16 114.66
Deferred Tax -0.08 -0.01 700.00 -0.08 -0.01 700.00 -0.08 -0.01 700.00
PAT -7.44 -4.07 82.80 7.05 4.08 72.79 7.05 4.08 72.79
Equity 44.81 44.81 0.00 44.81 44.81 0.00 44.81 44.81 0.00
PBIDTM(%) -13.46 -10.62 26.77 7.01 4.51 55.52 7.01 4.51 55.52
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..